{
    "ticker": "SNGX",
    "name": "Soligenix, Inc.",
    "description": "Soligenix, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat rare diseases and medical conditions with significant unmet needs. Founded in 2006 and headquartered in Princeton, New Jersey, Soligenix leverages its proprietary technologies to advance its pipeline of therapeutic candidates. The company is particularly recognized for its work in the fields of oncology, inflammation, and biodefense. Soligenix's lead product candidate, HyBryte (SGX301), is a novel photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL), which has received orphan drug designation from the FDA. The company is also developing products aimed at addressing gastrointestinal diseases and countermeasures for chemical and biological threats, such as its heat-stable formulation of the anthrax vaccine. With a commitment to innovation and patient care, Soligenix strives to bring forward therapies that can significantly improve the quality of life for patients suffering from these conditions. The company's mission is to create a sustainable future in healthcare by focusing on rare diseases and utilizing advanced drug delivery systems.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Princeton, New Jersey, USA",
    "founded": "2006",
    "website": "https://www.soligenix.com",
    "ceo": "Christopher J. Schaber",
    "social_media": {
        "twitter": "https://twitter.com/Soligenix",
        "linkedin": "https://www.linkedin.com/company/soligenix/"
    },
    "investor_relations": "https://www.soligenix.com/investors",
    "key_executives": [
        {
            "name": "Christopher J. Schaber",
            "position": "CEO"
        },
        {
            "name": "Richard D. S. O'Connor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "HyBryte (SGX301)"
            ]
        },
        {
            "category": "Gastrointestinal",
            "products": [
                "SGX942"
            ]
        },
        {
            "category": "Biodefense",
            "products": [
                "TheraT and Vaxart"
            ]
        }
    ],
    "seo": {
        "meta_title": "Soligenix, Inc. | Biopharmaceuticals for Rare Diseases",
        "meta_description": "Explore Soligenix, Inc., a biopharmaceutical company dedicated to developing innovative therapies for rare diseases. Learn about our pipeline and commitment to patient care.",
        "keywords": [
            "Soligenix",
            "Biopharmaceuticals",
            "Rare Diseases",
            "Oncology",
            "CTCL",
            "Biodefense"
        ]
    },
    "faq": [
        {
            "question": "What does Soligenix focus on?",
            "answer": "Soligenix focuses on developing therapeutics for rare diseases and medical conditions with unmet needs."
        },
        {
            "question": "What is the lead product candidate of Soligenix?",
            "answer": "The lead product candidate is HyBryte (SGX301), a treatment for cutaneous T-cell lymphoma."
        },
        {
            "question": "Where is Soligenix headquartered?",
            "answer": "Soligenix is headquartered in Princeton, New Jersey, USA."
        },
        {
            "question": "When was Soligenix founded?",
            "answer": "Soligenix was founded in 2006."
        }
    ],
    "competitors": [
        "SGMO",
        "CRMD",
        "VYGR",
        "APTO"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}